Satyendra Suryawanshi

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi et al. · Clinical Cancer Research · 2016 · 394 citations · Full text

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

Paolo A. Ascierto, Ignacio Melero, Shailender Bhatia et al. · Journal of Clinical Oncology · 2017 · 238 citations

Immunology, Immune Regulation, Immunoediting +24

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska et al. · Annals of Oncology · 2017 · 231 citations · Full text

Effect of Vinca rosea extracts in treatment of alloxan diabetes in male albino rats.

Sujoy Ghosh, Satyendra Suryawanshi · PubMed · 2001 · 226 citations

Lipid Peroxidation, Insulin Signaling, Oxidative Stress +18

Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

Paolo A. Ascierto, Petri Bono, Shailender Bhatia et al. · Annals of Oncology · 2017 · 146 citations · Full text